Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 48 results for leg ulcers

  1. EpiFix for chronic wounds (MIB139)

    NICE has developed a medtech innovation briefing (MIB) on EpiFix for chronic wounds .

    Medtech innovation briefing
    Published
    30 January 2018

  2. Granulox for managing chronic non-healing wounds (MIB296)

    NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .

    Medtech innovation briefing
    Published
    10 May 2022

  3. 3C Patch for treating diabetic foot ulcers (MTG66)

    Evidence-based recommendations on 3C Patch for treating diabetic foot ulcers.

    Medical technologies guidance
    Published
    7 March 2022
    View recommendations

    Sections for MTG66

  4. Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds (MIB11)

    NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds

    Medtech innovation briefing
    Published
    19 November 2014

  5. Diabetic foot problems: prevention and management (NG19)

    This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.

    NICE guideline
    Last updated
    11 October 2019
    View recommendations

    Sections for NG19

  6. NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds (MIB208)

    NICE has developed a medtech innovation briefing (MIB) on NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds .

    Medtech innovation briefing
    Published
    17 March 2020

  7. The committee recommends collecting further data on the impact of the automated devices on time to treatment for people with leg ulcers to reduce uncertainty in the economic modelling.

    the impact of the automated devices on time to treatment for people with leg ulcers to reduce uncertainty in the economic modelling. Any...

    Research recommendation
    Published
    11 July 2023

  8. The committee recommends more research on diagnostic accuracy in people with leg ulcers. The following considerations should be made when doing this research:

    committee recommends more research on diagnostic accuracy in people with leg ulcers. The following considerations should be made when...

    Research recommendation
    Published
    11 July 2023

  9. MolecuLight i:X for wound imaging (MIB212)

    NICE has developed a medtech innovation briefing (MIB) on MolecuLight i:X for wound imaging .

    Medtech innovation briefing
    Published
    18 June 2020

  10. Cost saving guidance

    NICE guidance that could generate cost savings.

  11. Subfascial endoscopic perforator vein surgery (IPG59)

    Evidence-based recommendations on subfascial endoscopic perforator vein surgery. This involves cutting and closing off, or heating and sealing, perforator veins so that blood can no longer go through them.

    Interventional procedures guidance
    Published
    27 May 2004
    View recommendations

    Sections for IPG59

  12. Randomised controlled trials comparing Prontosan with saline or water in the NHS are needed. The committee concluded that further research is needed to address the uncertainties about the clinical effectiveness of Prontosan compared with saline or water. It recommended that randomised controlled trials should be done in the NHS. These should compare Prontosan with saline or water in different types of chronic wounds. The randomised controlled trial needs to be well designed to detect clinically meaningful results in subgroups (for example, pressure ulcers or venous leg ulcers). The committee agreed that a key outcome should be time to complete wound healing. The number of dressing changes should also be recorded for each wound included in the study. Other important outcomes should include pain and wound odour, measured using patient reported outcome measures (PROMs).

    clinically meaningful results in subgroups (for example, pressure ulcers or venous leg ulcers). The committee agreed that a...

    Research recommendation
    Published
    8 April 2022

  13. The Versajet II hydrosurgery system for surgical debridement of acute and chronic wounds and burns (MIB1)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Versajet II hydrosurgery system

    Medtech innovation briefing
    Published
    4 February 2014

  14. Venous leg ulcers - new treatments [ID394]

    Discontinued [GID-TAG370]

    Technology appraisal guidance
    Discontinued

  15. Woundchek Protease Status for assessing elevated protease status in chronic wounds (MIB83)

    NICE has developed a medtech innovation briefing (MIB) on the Woundchek Protease Status for assessing elevated protease status in chronic wounds .

    Medtech innovation briefing
    Published
    5 October 2016